Figure 2.
Change of serum HBeAg level and proportion of patients with HBeAg sero-response. HBeAg levels in CHB patients in the IFN+TDF group decreased more rapidly during the 48-week treatment (A), we did not observe significant differences in HBeAg serological loss or seroconversion rates between the two groups at weeks 24 and 48 (B and C).
Abbreviations: CHB, chronic hepatitis B; IFN, interferon; TDF, tenofovir.